Adial Pharmaceuticals Inc (ADIL)
NASDAQ:ADIL
Top Page
Adial Pharmaceuticals
(NASDAQ:ADIL)
Select Model
Select Model
Rating:44Neutral
Price Target:
$2.00
▲(809.09% Upside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by weak financial performance (no revenue, sustained losses, and persistent cash burn) and bearish technicals (below key moving averages with negative MACD). Corporate events provide a modest offset via regained Nasdaq compliance and a potential European partnership, but valuation remains constrained by negative earnings.
Positive Factors
Low leverage
A minimal-debt profile materially reduces near-term solvency risk for a cash-burning biotech. Low leverage preserves strategic optionality to raise capital or pursue partnerships without large interest burdens, helping the firm sustain clinical programs while avoiding immediate debt constraints.
Negative Factors
No revenue / persistent losses
Absent product revenue, the company's economics depend entirely on external funding or milestone/licensing events. Chronic operating losses erode equity over time and leave no internal path to margin improvement until a successful commercialization event occurs, heightening execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
A minimal-debt profile materially reduces near-term solvency risk for a cash-burning biotech. Low leverage preserves strategic optionality to raise capital or pursue partnerships without large interest burdens, helping the firm sustain clinical programs while avoiding immediate debt constraints.
Read all positive factors
Adial Pharmaceuticals (ADIL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.24M
Dividend YieldN/A
Average Volume (3M)746.19K
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue GrowthN/A
EPS Growth78.52%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.81
Shares Outstanding1,427,970
10 Day Avg. Volume779,793
30 Day Avg. Volume746,186
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap-1.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.46K
Enterprise Value/Ebitda0.56
Forecast
1Y Price Target
$8.00Price Target Upside3536.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-6.73
Revenue Forecast (FY)N/A
Adial Pharmaceuticals Business Overview & Revenue Model
Company Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, w...
How the Company Makes Money
null...
Adial Pharmaceuticals Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
46
Neutral
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -565.00 | 0.00 | -564.00 | 0.00 | 0.00 |
| EBITDA | -7.80M | -8.28M | -7.00M | -10.86M | -17.69M |
| Net Income | -7.98M | -13.20M | -7.00M | -12.73M | -19.42M |
Balance Sheet | |||||
| Total Assets | 6.67M | 5.04M | 4.74M | 5.73M | 7.63M |
| Cash, Cash Equivalents and Short-Term Investments | 5.88M | 3.75M | 2.83M | 4.00M | 6.06M |
| Total Debt | 0.00 | 0.00 | 0.00 | 207.38K | 256.96K |
| Total Liabilities | 1.40M | 975.86K | 653.51K | 2.46M | 4.13M |
| Stockholders Equity | 5.28M | 4.07M | 4.08M | 3.28M | 3.51M |
Cash Flow | |||||
| Free Cash Flow | -6.49M | -6.92M | 0.00 | -11.19M | -12.01M |
| Operating Cash Flow | -6.49M | -6.92M | -6.81M | -11.19M | -11.95M |
| Investing Cash Flow | 150.00K | 0.00 | 1.50M | 0.00 | -34.02K |
| Financing Cash Flow | 8.47M | 7.85M | 4.13M | 9.13M | 13.64M |
Adial Pharmaceuticals Technical Analysis
Negative
0.22
Price Trends
2.44
Negative
4.55
Negative
7.01
Negative
Market Momentum
-0.24
Negative
32.73
Neutral
8.60
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADIL, the sentiment is Negative. The current price of 0.22 is below the 20-day moving average (MA) of 1.75, below the 50-day MA of 2.44, and below the 200-day MA of 7.01, indicating a bearish trend. The MACD of -0.24 indicates Negative momentum. The RSI at 32.73 is Neutral, neither overbought nor oversold. The STOCH value of 8.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADIL.
Adial Pharmaceuticals Risk Analysis
Adial Pharmaceuticals disclosed 66 risk factors in its most recent earnings report. Adial Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Adial Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $9.76M | -0.31 | -32.58% | ― | -100.00% | -463.97% | |
44 Neutral | $2.24M | -0.46 | -155.01% | ― | ― | 78.52% | |
43 Neutral | $4.89M | -0.31 | -46.34% | ― | ― | 70.71% | |
42 Neutral | $3.20M | -0.42 | -157.24% | ― | ― | 25.19% | |
40 Underperform | $2.79M | -0.52 | ― | ― | ― | 87.42% |
* Healthcare Sector Average
ADIL
Adial Pharmaceuticals
1.57
-16.55
-91.34%
GLMD
Galmed Pharmaceuticals
0.74
-0.59
-44.29%
KPRX
Kiora Pharmaceuticals
2.47
-0.29
-10.51%
MTNB
Matinas BioPharma
0.50
-0.08
-13.79%
ALZN
Alzamend Neuro
0.86
-6.24
-87.93%
CLDI
Calidi Biotherapeutics
0.26
-4.95
-95.09%
Adial Pharmaceuticals Corporate Events
Executive/Board Changes
Adial Pharmaceuticals Implements New Executive Equity Compensation Plan
Neutral
Apr 9, 2026
On April 7, 2026, Adial Pharmaceuticals’ Compensation Committee approved grants of restricted stock awards to key executives, including 37,985 shares to Chief Executive Officer and Director Cary Claiborne, 17,325 shares to Chief Financial Of...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Adial Pharmaceuticals Secures European Partnership for AD04 Commercialization
Positive
Mar 3, 2026
On March 3, 2026, Adial Pharmaceuticals announced a collaboration framework with Italy’s Molteni Farmaceutici for a proposed exclusive partnership to commercialize its lead addiction drug candidate AD04 in Europe, giving Molteni a period of ...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Adial Pharmaceuticals Regains Nasdaq Compliance, Advances AD04 Program
Positive
Feb 24, 2026
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in genetically targeted therapies for addiction, is advancing its lead candidate AD04 for Alcohol Use Disorder into a new Phase 3 program. The company is building...
Regulatory Filings and ComplianceShareholder MeetingsStock Split
Adial Pharmaceuticals Implements Reverse Stock Split to Regain Compliance
Neutral
Feb 4, 2026
On August 1, 2025, shareholders of Adial Pharmaceuticals approved a reverse stock split of the company’s common stock, and the board later set the final ratio at 1-for-25, with the split becoming legally effective at 11:59 p.m. Eastern Time ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.